Indaptus Therapeutics announced its Q3 2026 financial results, highlighting a net loss reduction to $1 million from $3 million year-over-year, and a significant decrease in R&D and administrative expenses. The company raised approximately $24 million through a private placement to fund working capital and new research, including early-stage development of a neurotechnology-based device targeting sleep-related conditions. With $30.6 million in cash and investments as of September 30, 2026, Indaptus aims to expand its strategic focus and pursue innovative medical opportunities, potentially leading to future FDA submissions.
Indaptus Therapeutics' Q3 2026 financial results provide context for readers. For those tracking the health sector, 71 of 150 US health stocks on Pluang rose while 75 fell as of Nov 14, 2026 04:11 WIB. Notable movers include Alnylam Pharmaceuticals, Inc. (ALNY) with a price of USD 165.74 and 100% buy order activity, Ginkgo Bioworks Holdings Inc (DNA) down 5.96% at USD 9.62 with 93% sell orders, and Summit Therapeutics Inc (SMMT) at USD 14.20 with 88% buy orders.
ArrowMark Financial Corp. announced a monthly cash distribution of $0.15 per share for November 2026, payable on November 30 to shareholders of record as of November 23. This distribution reflects the company's ongoing commitment to provide current i...
Liberty Defense Holdings clarified details of its credit facility and term loan with Parabilis, originally announced in 2024. The company’s subsidiary received a $1.8 million term loan and a $2.5 million revolving credit facility, both secured by sub...
Stardust Power announced a $2.8 million net loss for Q3 2026, an improvement from $4.5 million last year, driven by lower administrative costs and warrant value changes. The company is progressing its lithium refinery project in Muskogee, Oklahoma, d...
byNordic Acquisition Corporation, a special purpose acquisition company, has extended its deadline to complete a business combination by one month, moving it from November 12, 2026, to December 12, 2026. This is the fourth of up to twelve possible on...
Texas Pacific Land Corporation reported a high Return on Invested Capital (ROIC) of 30.81%, significantly surpassing its Weighted Average Cost of Capital (WACC) of 7.73%. This strong performance results in the highest ROIC-to-WACC ratio of 3.98 among...
